People · Operator
Named in public records as an officer, director or promoter · active 2020–2024 · Pharma, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pear Therapeutics, Inc. | — | Pharma | Series D+ | $254.8M | $4.1B | 2020 |
| Variant Bio, Inc. | — | Biotechnology | Series D+ | $127.7M | $2.8B | 2021 |
| CTRL Therapeutics USA, Inc. | — | Biotechnology | Series A | $16.6M | $43.1M | 2022 |
| Medeloop, Inc. | — | Other | Series B | $15.5M | $89.9M | 2024 |
Elena Viboch at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Elena Viboch on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Schwab | 1 | 16 |
| Adam Goulburn | 1 | 10 |
| Stuart Nagae | 1 | 9 |
| Timothy Petersen | 1 | 9 |
| Josh Wolfe | 1 | 8 |
| Andrew J. Schwab | 1 | 7 |
| Bob More | 1 | 6 |
| Corey McCann | 1 | 5 |
| Julie Sunderland | 1 | 5 |
| DAVID O'NEILL | 1 | 4 |
| Magaly Charbonneau | 1 | 2 |
| Alex Waldron | 1 | 2 |
| Zack Lynch | 1 | 2 |
| ANTOUN NABHAN | 1 | 2 |
| Michael Kalos | 1 | 2 |
| Amir Dan Rubin | 1 | 2 |
| Yuri Maricich | 1 | 1 |
| Ronan O'Brien | 1 | 1 |
| Jeremy Gilbert | 1 | 1 |
| Hongjie Hu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.